Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 78,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average price of $4.22 per share, for a total transaction of $329,160.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $12,950,973.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, February 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were acquired at an average price of $4.14 per share, for a total transaction of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The shares were acquired at an average price of $4.30 per share, for a total transaction of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The shares were acquired at an average price of $4.47 per share, for a total transaction of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The shares were acquired at an average price of $4.90 per share, for a total transaction of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were acquired at an average price of $4.89 per share, for a total transaction of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were acquired at an average price of $4.40 per share, for a total transaction of $440,000.00.

Opko Health Inc. (NASDAQ:OPK) opened at $4.15 on Thursday. The firm has a market cap of $2,427.82, a PE ratio of -18.82 and a beta of 1.42. Opko Health Inc. has a 12 month low of $4.01 and a 12 month high of $8.92. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.03) earnings per share. equities analysts anticipate that Opko Health Inc. will post -0.27 earnings per share for the current fiscal year.

A number of equities research analysts have recently commented on OPK shares. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $13.34.

A number of institutional investors have recently modified their holdings of OPK. Crossmark Global Holdings Inc. purchased a new position in Opko Health in the 3rd quarter valued at about $118,000. State of Alaska Department of Revenue purchased a new position in Opko Health in the 4th quarter valued at about $144,000. The Manufacturers Life Insurance Company lifted its stake in Opko Health by 7.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,657 shares in the last quarter. Psagot Investment House Ltd. lifted its stake in Opko Health by 20.0% in the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 3,806 shares in the last quarter. Finally, Prudential Financial Inc. lifted its stake in Opko Health by 6.1% in the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 1,400 shares in the last quarter. 22.94% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Insider Buying: Opko Health Inc. (OPK) CEO Acquires 78,000 Shares of Stock” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2018/02/08/insider-buying-opko-health-inc-opk-ceo-acquires-78000-shares-of-stock.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.